AAPG
Ascentage Pharma Group International (AAPG) PESTLE Analysis Analysis (2026)
Overall Score
Political
No material political developments were provided in the latest news flow.
The company’s operating profile remains primarily driven by internal execution and commodity exposure rather than policy changes.
Economic
Valuation remains elevated with EV/Sales at 19.8x and Price/Sales at 20.7x, leaving limited margin for error.
Profitability and cash generation remain weak, with negative TTM free cash flow yield and negative operating cash flow metrics.
Liquidity is still adequate, with a current ratio of 1.79x and cash ratio of 1.50x.
Social
No new social or consumer-demand developments were reported this month.
There is no fresh evidence of a meaningful shift in customer perception or workforce-related issues.
Technological
R&D intensity remains elevated at 2.0% of revenue, but no new product or technology catalyst was reported.
No material change in the company’s technology posture was indicated in the fresh data.
Legal
No new litigation, regulatory, or compliance developments were reported in the latest news.
Interest coverage remains very weak on a TTM basis, which could heighten sensitivity to financing and covenant-related issues if conditions worsen.
Environmental
No new environmental or ESG-related developments were reported this month.
Capital intensity remains modest relative to revenue, but the fresh data does not indicate a material shift in environmental risk.
Sources
- Company filings (10-K, 10-Q, investor presentations)
- Financial and market data providers
- Public news and industry information
🔒 Go Beyond This Framework
This is one of 10 institutional-grade frameworks Invetso runs on Ascentage Pharma Group International. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

